Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-α therapy: Including quantitative assessment by a morphometric method

Journal of Gastroenterology

Volumn 35, Issue 2, 2000, Pages 105-111

  Yagura, Michiyasu ^a   Murai, Seiyou ^a   Kojima, Hiroshi ^a   Tokita, Hajime ^a   Kamitsukasa, Hiroshi ^a   Harada, Hideharu ^a  

^a National Hospital Organization   (Japan)

Author keywords

Chronic hepatitis C; Interferon ; Liver fibrosis; Morphometric image analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIFIBROTIC AGENT; BUPLEURUM ROOT; NEOMINOPHAGEN C; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0034010529     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350050022     Document Type: Article

References (21)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer H, Perillo R, et al. Treatment of chronic hepatitis C with recombinant interfcron alpha: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1494-500.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray LWJ, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double blind, placebo controlled trial. N Engl J Med 1989;321:1506-10.
3. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
4. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-99.
5. Cammps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomized trial of lymphoblastoid-α interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993;17: 390-6.
6. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propeptide of type III collagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1995;22:426-31.
7. Capra F, Casaril M, Gabriell GB, Tognella P, Rizzi A, Dolci L, et al. Interferon-α in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993;18:112-8.
8. Lopez de Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737-43.
9. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, et al. Interferon-α 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;18:1344-9.
10. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collage synthesis of human Ho cells in culture. Hepatology 1995; 21:1103-10.
11. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, et al. Interferon gamma decreases hepatic stellate cell activation and matrix deposition in rat liver fibrosis. Hepatology 1996;23:1189-99.
12. Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K, Okita K. Inteferon γ - but not α-treatment prevents fihrosis by inhibiting procollagen and tissue inhibitor of metalloproteinase-1 gene expression in pig serum-induced rat liver fibrosis in vivo. Hepatology Res 1998;12:59-67.
13. Desmet VJ, Gerber M, Hoofnagel JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
14. Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M. Timple R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. EurJ Clin Invest 1979;9:451-9.
15. Nakayashi H, Takamatsu S, Nakato H. A simply estimation of liver collagen content by the computed color image analysis using sirius red stained sections. Acta Hepatol Jap 1993;34:212-8.
16. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud J-A. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle biopsy specimens: comparison with morphometric studies. Hepatology 1994;20:349-55.
17. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 1997;25:1028-31.
18. Yabu K, Kiyosawa K, Mori H, Furuta S. Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 1994;29:474-9.
19. Guéchot J, Eoria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fihrosis in chronic viral hepatitis C: effect of α-interferon therapy. J Hepatol 1995;22:22-6.
20. Ueno T, Torimura T, Inuzuka S, Ishii K, Yoshitake M, Kosaka S, et al. Serum type III procollagen N peptide (PIIIP) and laminin levels and hepatic immunohistochemical study in patients with various liver diseases. Acta Hepatol Jpn 1989;30:429-38.
21. Castilla A, Prieto J, Fausto N. Transforming growth factors β 1 and α in chronic liver disease: effects of interferon alfa therapy. New Engl J Med 1991;324:933-40.